#diranersen
Patients who took part in a major trial and received low-dose diranersen injections showed 54% less decline on a memory and thinking test over nearly two years. The diranersen injection is also the first to show lower levels of tau.
(£) www.thetimes.com/uk/healthcar...
Biannual jab ‘reduces cognitive decline’ in Alzheimer’s patients
Patients who received the diranersen injection in a trial showed 54 per cent less decline on a memory and thinking test
www.thetimes.com
November 20, 2026 at 12:09 PM
A jab given just 2xs a year has halved the rate of cognitive decline in Alzheimer’s patients, with scientists describing the results as “thrilling”. In a major trial, patients given low-dose diranersen injections showed 54% less decline on a test of memory and thinking over almost two years.
November 19, 2026 at 11:17 PM
Patients who received the diranersen injection in a trial showed 54 per cent less decline on a memory and thinking test 👉 www.thetimes.com/uk/healthc...
November 19, 2026 at 12:21 AM
BREAKING: A new Alzheimer's drug slowed cognitive decline by 54% in a Phase II trial, researchers report. Diranersen targets tau, given twice a year, and the benefit grew over two years. #BreakingNews #Science #Alzheimers #Biogen #Health #Research #Medicine #BrainHealth #Biotech #MedicalNews
November 20, 2026 at 5:43 PM
Alzheimer's jab halves decline with one injection every six months, study finds
www.lbc.co.uk/article/alzh...
Alzheimer's jab halves decline with one injection every six months, study find. | LBC
Diranersen trials showed a 54% decline in the progression of the disease
www.lbc.co.uk
November 18, 2026 at 9:27 PM
Low-dose diranersen injections halved cognitive decline in Alzheimer’s patients over nearly two years by reducing tau production.
Save What Matters
Curate Feeds | Make Collections | Customize Email Briefs
briefly.co
November 20, 2026 at 9:25 AM
Low-dose diranersen injections halved cognitive decline in Alzheimer’s patients over nearly two years by reducing tau production.
Save What Matters
Curate Feeds | Make Collections | Customize Email Briefs
briefly.co
November 20, 2026 at 12:38 AM
New Developments in Combination Therapies for Alzheimer’s Disease Highlighted at CTAD Conference#United_States#Boston#Biogen#Alzheimer's#diranersen
New Developments in Combination Therapies for Alzheimer’s Disease Highlighted at CTAD Conference
Biogen shared promising findings from the Phase 2 CELIA study at the CTAD conference, indicating potential benefits of diranersen in treating early Alzheimer's disease.
third-news.com
November 18, 2026 at 4:45 PM
📈 TeraWulf shares rise after Nvidia's Q3 results.
🧠 Biogen reports two-year CELIA data on diranersen.
⚠️ Anthropic founders warn of authoritarian AI surveillance.
November 18, 2026 at 9:22 PM
Alzheimer tedavisinde tau proteinini hedefleyen yeni ilaç umut oldu
Alzheimer tedavisinde tau proteinini hedefleyen yeni ilaç umut oldu
Deneysel diranersen ilacı, Alzheimer hastalarında bilişsel gerilemeyi yüzde 54 oranında yavaşlatarak hastalıkla mücadelede yeni bir kapı araladı.
dlvr.it
November 19, 2026 at 11:36 AM
An experimental Alzheimer's drug, diranersen, was linked to 54% less decline on a memory and thinking test over almost two years, and scans showed tau tangles falling 🧠

Caveats: it missed its phase 2 main goal and isn't approved. Phase 3 is planned.

#Alzheimers #Science
Alzheimer's Drug Slows Memory Decline by 54% and Removes Harmful Brain Protein Tangles
Biogen's experimental Alzheimer's drug diranersen was associated with 54 per cent slower decline on a memory and thinking test over almost two years, although its phase two trial missed its primary…
www.medicaldaily.co.uk
November 20, 2026 at 2:55 PM
Access Denied
investors.biogen.com
November 18, 2026 at 9:08 AM
MHRA awards ILAP Innovation Passports to three pre-confirmatory therapies, signalling early-access intent before confirmatory data. https://www.mattheneus.com/editorial/mhra-ilap-innovation-passport-awards-brezosiran-bgb58067-diranersen-2026-11-09 #HTA #RegulatoryAffairs
November 18, 2026 at 8:04 AM
Watching Biogen $BIIB: diranersen MAPT ASO lowers CSF p-tau, 38% CDR-SB at 2y. Mechanisitc rescue; lens refocussed, market mispriced-call +45% rerate. https://endpoints.news/ctad26-biogens-tau-drug-slows-alzheimers-more-after-nearly-two-years/
November 18, 2026 at 5:03 PM
Biogen’s tau-silencing drug diranersen slows Alzheimer’s by 38% after nearly two years, up from 26% slowing after 18 months, according to data at #CTAD26. But lots of caveats, including a small group and imperfect placebo comparison. Details in @endpts.com - endpoints.news/ctad26-bioge...
Biogen says low dose of its experimental tau-reducing drug fares even better after nearly 2 years
Biogen's diranersen slowed Alzheimer's progression 38% after ~2 years vs 26% at 18 months, per data at CTAD Boston. Phase 3 trial planned.
endpoints.news
November 18, 2026 at 1:15 AM
Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. #CTAD26
https://www.medpagetoday.com/meetingcoverage/ctad/123956
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
Open-label extension data suggest diranersen's treatment effects may build over time
www.medpagetoday.com
November 19, 2026 at 1:05 AM
Ex-PI: Biogen $BIIB MAPT ASO knocks MAPT mRNA, lowers CSF p-tau; focus. https://longevity.technology/news/biogens-tau-drug-diranersen-gets-a-ctad-spotlight/
November 11, 2026 at 4:03 PM
Ex-PI: Biogen runs a MAPT ASO (diranersen). Robust MAPT mRNA knockdown should lower CSF p-tau and align tau PET at 96w - concordance will rerate $BIIB. Focus, exposure, perspectve; quantatative analysis. https://longevity.technology/news/biogens-tau-drug-diranersen-gets-a-ctad-spotlight/
November 10, 2026 at 8:08 PM
Ex-PI: Biogen and $BIIB run a MAPT ASO. Robust MAPT mRNA knockdown should lower CSF p-tau and tau PET; 96-week biomarker concordance will rerate the stock. Focus, exposure, perspectve. https://longevity.technology/news/biogens-tau-drug-diranersen-gets-a-ctad-spotlight/
November 10, 2026 at 3:04 PM
Watching $BIIB and Biogen: diranersen ASO reduces MAPT mRNA; CSF p-tau + tau PET are focus/exposure. If 96wk concordance I call +30% rerate. https://investors.biogen.com/news-releases/news-release-details/biogen-present-new-data-across-alzheimers-disease-portfolio-ctad
November 7, 2026 at 9:06 PM
【タウ標的薬の96週データと、レカネマブの5年追跡を発表】
Biogenが、CTAD 2026でアルツハイマー病領域の新データを発表する。タウ標的のdiranersen(BIIB080)は第2相CELIA試験の96週長期延長データを出す。lecanemabはClarity AD非盲検延長の5年間データと、LEADER試験の3年間実臨床データを示す。Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
stellanews.life/technology/1...
Biogen、CTAD2026でアルツハイマー病領域の新データを発表──タウ標的diranersenは第2相で96週延長データ、レカネマブは5年間の長期追跡データを公表
Biogen社は2026年11月のCTAD会議で、タウ標的の開発中薬剤diranersenの第2相CELIA試験に関する96週長期延長データと、lecanemab(レカネマブ)の5年間長期追跡・実臨床データを発表する。
stellanews.life
November 6, 2026 at 8:38 AM